Financial Performance - The company's operating revenue for Q1 2025 was RMB 618,542,128.87, a decrease of 4.25% compared to RMB 645,995,271.22 in the same period last year[9]. - Net profit attributable to shareholders for Q1 2025 was RMB 90,312,072.67, down 7.41% from RMB 97,541,532.98 year-on-year[9]. - The net profit after deducting non-recurring gains and losses was RMB 88,474,729.61, reflecting a decrease of 7.08% compared to RMB 95,217,851.02 in the previous year[9]. - The total revenue for the first quarter of 2025 was CNY 618,542,128.87, a decrease of approximately 4.5% compared to CNY 645,995,271.22 in the first quarter of 2024[24]. - The operating profit for the first quarter of 2025 was CNY 103,806,860.81, compared to CNY 114,427,839.61 in the first quarter of 2024, indicating a decline of approximately 9.1%[24]. - Net profit for Q1 2025 was approximately ¥83.81 million, a decrease of 9.1% compared to ¥92.49 million in Q1 2024[25]. - Total comprehensive income for Q1 2025 reached approximately ¥106.29 million, an increase of 49.2% from ¥71.27 million in Q1 2024[25]. - Basic and diluted earnings per share for Q1 2025 were both RMB 0.39, down 7.14% from RMB 0.42 in the same period last year[9]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.39, down from ¥0.42 in Q1 2024[25]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 13.04% to RMB 85,876,398.75, compared to RMB 75,969,702.64 in the same period last year[9]. - Cash flow from operating activities for Q1 2025 was approximately ¥85.88 million, an increase of 13.5% compared to ¥75.97 million in Q1 2024[28]. - Cash flow from investing activities for Q1 2025 showed a net outflow of approximately ¥179.29 million, compared to a net inflow of ¥159.29 million in Q1 2024[28]. - Cash flow from financing activities for Q1 2025 resulted in a net outflow of approximately ¥79.08 million, compared to a net inflow of ¥42.14 million in Q1 2024[29]. - The cash and cash equivalents as of March 31, 2025, were CNY 2,544,062,908.38, a decrease from CNY 2,630,205,433.37 as of December 31, 2024[21]. - The cash and cash equivalents at the end of Q1 2025 were approximately ¥944.67 million, an increase from ¥846.19 million at the end of Q1 2024[29]. Research and Development - Research and development expenses totaled RMB 48,418,019.42, a decrease of 25.40% from RMB 64,900,123.30 year-on-year[9]. - R&D expenses accounted for 7.83% of operating revenue, down from 10.05% in the previous year, a reduction of 2.22 percentage points[9]. - The company reported a decrease in R&D expenses to CNY 48,418,019.42 in the first quarter of 2025, down from CNY 64,900,123.30 in the same period last year, reflecting a reduction of approximately 25.5%[24]. Assets and Equity - Total assets at the end of the reporting period were RMB 7,127,388,076.14, a slight increase of 0.08% from RMB 7,121,392,176.35 at the end of the previous year[9]. - Equity attributable to shareholders increased by 1.68% to RMB 5,669,029,445.16 from RMB 5,575,258,634.87 at the end of the previous year[9]. - The total liabilities as of March 31, 2025, were CNY 1,175,145,054.36, a decrease from CNY 1,204,351,783.01 as of December 31, 2024[22]. - The equity attributable to shareholders as of March 31, 2025, was CNY 5,669,029,445.16, an increase from CNY 5,575,258,634.87 at the end of 2024[22]. Inventory and Costs - The company's inventory as of March 31, 2025, was CNY 488,198,643.67, slightly down from CNY 490,650,955.52 at the end of 2024[21]. - The total operating costs for the first quarter of 2025 were CNY 510,997,863.52, down from CNY 535,026,579.06 in the same period last year, reflecting a reduction of about 4.5%[24]. - The company experienced a significant increase in other comprehensive income, with a net amount of approximately ¥22.48 million in Q1 2025, compared to a loss of ¥21.22 million in Q1 2024[25]. Capital Changes - The company completed a capital reserve conversion to increase share capital, issuing 66,782,692 new shares in 2024[9].

Financial Performance - The company's operating revenue for Q1 2025 was ¥618,542,128.87, a decrease of 4.25% compared to ¥645,995,271.22 in the same period last year[4] - The net profit attributable to shareholders was ¥90,312,072.67, down 7.41% from ¥97,541,532.98 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥88,474,729.61, reflecting a decrease of 7.08% compared to ¥95,217,851.02 in the previous year[4] - Total revenue for Q1 2025 was ¥618.54 million, a decrease of 4.9% compared to ¥645.99 million in Q1 2024[16] - Net profit for Q1 2025 was ¥83.81 million, a decline of 9.4% from ¥92.49 million in Q1 2024[16] - Basic earnings per share for Q1 2025 were ¥0.39, compared to ¥0.42 in Q1 2024[17] Cash Flow - The net cash flow from operating activities increased by 13.04% to ¥85,876,398.75, compared to ¥75,969,702.64 in the same period last year[4] - In Q1 2025, the net cash flow from operating activities was ¥85,876,398.75, an increase of 13.5% compared to ¥75,969,702.64 in Q1 2024[19] - Total cash inflow from operating activities was ¥640,948,930.38, down 9.1% from ¥705,232,753.89 in the previous year[19] - The net cash flow from investing activities was -¥179,294,387.16, a significant decrease from ¥159,290,447.77 in Q1 2024[19] - The net cash flow from financing activities was -¥79,079,486.98, compared to a positive cash flow of ¥42,137,675.19 in Q1 2024[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,127,388,076.14, a slight increase of 0.08% from ¥7,121,392,176.35 at the end of the previous year[5] - Total assets as of March 31, 2025, amounted to ¥7.13 billion, slightly up from ¥7.12 billion at the end of 2024[14] - Total liabilities decreased to ¥1.18 billion as of March 31, 2025, from ¥1.20 billion at the end of 2024[14] - The company’s total equity increased to ¥5.95 billion as of March 31, 2025, from ¥5.92 billion at the end of 2024[14] Research and Development - Research and development expenses totaled ¥48,418,019.42, a decrease of 25.40% from ¥64,900,123.30 year-on-year[4] - Research and development expenses for Q1 2025 were ¥48.42 million, a decrease of 25.5% from ¥64.90 million in Q1 2024[16] - The proportion of R&D expenses to operating revenue was 7.83%, down from 10.05% in the previous year, a reduction of 2.22 percentage points[4] Inventory and Cash Equivalents - The company reported an increase in inventory to ¥488.20 million as of March 31, 2025, compared to ¥490.65 million at the end of 2024[13] - Cash and cash equivalents were ¥2.54 billion as of March 31, 2025, down from ¥2.63 billion at the end of 2024[13] - The total cash and cash equivalents at the end of Q1 2025 were ¥944,673,243.30, an increase from ¥846,192,318.84 in Q1 2024[20] Non-Recurring Gains - The company reported non-recurring gains of ¥1,837,343.06 for the period, primarily from government subsidies and asset disposals[7]

上海昊海生物科技股份有限公司章程 1 | 第一章 | 总则 | 3 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 5 | | 第三章 | 股份和注册资本 | 5 | | 第四章 | 减资和购回股份 | 10 | | 第五章 | 股票和股东名册 | 11 | | 第六章 | 股东的权利和义务 | 12 | | 第七章 | 股东大会 | 15 | | 第八章 | 类别股东表决的特别程序 | 30 | | 第九章 | 董事会 | 32 | | 第十章 | 公司董事会秘书 | 40 | | 第十一章 | 公司总经理 | 40 | | 第十二章 | 监事会 | 42 | | 第十三章 | 公司董事、监事、总经理和其他高级管理人员的资格和义务 | 45 | | 第十四章 | 财务会计制度与利润分配 | 47 | | 第十五章 | 会计师事务所的聘任 | 52 | | 第十六章 | 公司的合并与分立 | 52 | | 第十七章 | 公司的解散和清算 | 53 | | 第十八章 | 通知与公告 | 55 | | 第十九章 | 公司章程的修订程序 | 57 | | 第二十章 | 附则 | 57 ...

昊海生科公告，2025年第一季度营收为6.19亿元，同比下降4.25%；净利润为9031.21万元，同比下降 7.41%。 ...

Financial Performance - The company reported a revenue of RMB 2,679.67 million for 2024, an increase of RMB 44.76 million, representing a growth of 1.70% compared to the previous year[10]. - Net profit attributable to shareholders was approximately RMB 420.45 million, remaining stable compared to the previous year[10]. - Gross profit for 2024 was RMB 1,868.79 million, with a gross margin of 69.7%[9]. - The company’s net profit margin was 15.6%, slightly down from 15.7% in the previous year[9]. - The company’s basic earnings per share for 2024 was RMB 1.80, compared to RMB 1.75 in 2023[9]. - The overall revenue for the company in the reporting period was approximately RMB 2,679.67 million, an increase of RMB 44.76 million or 1.70% from RMB 2,634.91 million in 2023[59]. - The company's gross profit margin for the reporting period was 69.74%, a slight decrease of 0.60 percentage points from 70.34% in 2023[61]. - Other income and gains for the reporting period amounted to approximately RMB 149.76 million, an increase of about RMB 15.47 million or 11.52% compared to RMB 134.29 million in 2023, primarily due to the recognition of performance compensation from minority shareholders of a subsidiary[62]. Research and Development - Research and development expenses amounted to RMB 238.93 million, an increase of RMB 18.83 million, reflecting a growth of about 8.56% and accounting for 8.92% of total revenue[11]. - R&D expenses for the reporting period were approximately RMB 238.93 million, an increase of about RMB 18.83 million or 8.56% from RMB 220.10 million in 2023, reflecting the company's ongoing investment in expanding its ophthalmology and medical aesthetics product lines[63]. - The company is actively developing advanced artificial lens products, including hydrophobic and hydrophilic extended depth of focus lenses, with clinical trials expected to begin in July 2024[39]. - The company is advancing its research on hydrophilic aspheric multifocal intraocular lenses, with clinical trials completed and registration expected in early 2025[42]. Product Development and Market Expansion - The company successfully launched the globally first organic cross-linked hyaluronic acid product "Hai Mei Yue Bai" in July 2024, and sodium hyaluronate eye drops were approved in March 2024[11]. - The company is expanding its product lines in aesthetic medicine and ophthalmology, with several key projects in clinical trials, including high oxygen permeability scleral lenses[11]. - The group’s hyaluronic acid product line achieved revenue of RMB 737.86 million in 2024, an increase of RMB 138.45 million, representing a growth rate of 23.10% compared to the previous year[28]. - The total revenue from medical beauty and wound care products reached RMB 1,189.22 million, up RMB 136.42 million, with a growth rate of approximately 12.96%[22]. - The company plans to expand the application of hEGF products into various medical fields, including pediatrics and oncology, beyond traditional uses[28]. - The company plans to focus on four rapidly developing treatment areas: medical beauty, wound care, ophthalmology, and orthopedics, emphasizing research and innovation[54]. Market Trends and Competitive Position - The market for non-surgical beauty treatments in China is expected to grow by about 10% in 2024, with a projected compound annual growth rate of 10-15% over the next four years[26]. - The Chinese medical beauty market size grew from RMB 99.3 billion in 2017 to RMB 189.2 billion in 2021, with a compound annual growth rate of 17.5%[24]. - The penetration rate of medical beauty treatments in China is significantly lower than in Brazil, the US, and South Korea, indicating potential for future market growth[24]. - The company achieved a market share increase in the orthopedic sector, rising from 46.54% in 2022 to 50.44% in 2023, solidifying its position as the leading manufacturer of viscoelastic supplements for joint injections in China[46]. Financial Management and Shareholder Returns - The company distributed a total of RMB 166,956,729.00 as final dividends and increased share capital by 66,782,692 shares by the end of July 2024[13]. - For the first half of 2024, the company distributed interim dividends totaling RMB 92,902,248.40[13]. - The board proposed a final dividend of RMB 0.6 per share (before tax) for the year ending December 31, 2024, totaling RMB 138,023,048.4 (before tax) based on the total issued shares of 233,193,695, after accounting for treasury shares[89]. - The company has adopted a dividend policy that emphasizes a balance between reasonable returns to investors and sustainable development[97]. - The company aims for a minimum cash dividend proportion of 80% for mature stages without significant capital expenditure[98]. Regulatory and Compliance - The company emphasizes the importance of environmental protection and has established and continuously improved its environmental management systems, ensuring compliance with pollution discharge standards[85]. - The company has not encountered any significant violations of environmental laws and regulations during the reporting period[85]. - The company has complied with all applicable provisions of the corporate governance code under the Hong Kong Listing Rules during the reporting period[186]. - There are no significant legal proceedings or arbitrations involving the company during the reporting period[187]. Employee and Management Structure - The company had approximately 2,156 employees as of December 31, 2024, with total employee compensation amounting to approximately RMB 692.94 million, an increase of about RMB 62.86 million from the previous year[70]. - The company’s employee compensation policy aims to enhance governance structure and motivate core teams to improve competitiveness[145]. - Non-executive directors receive fixed remuneration based on their background, experience, and responsibilities, with no additional director remuneration for executive directors[144]. Share Repurchase and Capital Management - The company repurchased 1,418,934 A-shares, accounting for 0.61% of total shares, with a total transaction amount of approximately RMB 106.27 million[13]. - A total of 2,492,100 H-shares were repurchased during the year, with a total expenditure of HKD 75,709,045.00[120]. - The board believes that the share repurchase enhances investor confidence and aligns the interests of shareholders, the company, and employees[121]. Governance and Stakeholder Engagement - The company maintains good relationships with stakeholders, including customers, shareholders, government agencies, employees, suppliers, and the community, to achieve medium- and long-term goals[86]. - The company has established a governance structure consisting of the general meeting of shareholders, the board of directors, the supervisory board, and the management team[195].

一、核心技术人员离职的具体情况 公司核心技术人员甘人宝先生因年事已高，不再担任公司核心技术人员。公司及董事会对甘人宝先生为 公司发展所做出的工作表示感谢。 （一）核心技术人员的基本情况 甘人宝，男，1939年出生，中国国籍，无境外居留权，本科学历，博士生导师。1960年10月至2004年6 月历任中国科学院上海生命科学研究院生物化学与细胞生物学研究所研究员、干部。甘人宝先生于2010 年7月加入公司，曾任公司副总经理、董事、非执行董事，离职前为公司核心技术人员。 截至本公告披露日，甘人宝先生未持有公司股份。 （二）甘人宝先生参与的研发项目和专利情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●上海昊海生物科技股份有限公司（以下简称"公司"）核心技术人员甘人宝先生因年事已高，不再担任 公司核心技术人员，其已办理完毕相关工作的交接手续。 ●截至本公告日，甘人宝先生未参加公司的在研项目，其离职不会对公司技术研发及生产经营带来实质 性影响，不会影响公司持有的核心技术，不存在涉及职务发明的纠纷或潜在纠纷。 二、 ...

Financial Performance - The company recorded a total revenue of RMB 2,679.67 million for the year ended December 31, 2024, representing an increase of RMB 44.76 million or 1.70% compared to the previous year[2]. - The net profit attributable to shareholders was approximately RMB 420.45 million, while the net profit excluding non-recurring items was RMB 379.10 million, remaining relatively stable compared to the previous year[2]. - The gross profit for the year was RMB 1,868.79 million, with a gross margin of approximately 69.9%[5]. - The group's profit before tax for 2024 reached RMB 810,788,000, an increase from RMB 781,162,000 in 2023, reflecting a growth of approximately 3.2%[38]. - The total tax expense for 2024 was RMB 89,902,000, a decrease from RMB 95,991,000 in 2023, indicating a reduction of about 6.5%[42]. - The overall gross profit margin for the group was 69.74%, a slight decrease of 0.60 percentage points from 70.34% in 2023[115]. - Profit attributable to ordinary equity holders was approximately RMB 420.45 million, an increase of about RMB 4.33 million or 1.04% compared to 2023[120]. Research and Development - Research and development expenses amounted to approximately RMB 238.93 million, an increase of RMB 18.83 million or 8.56%, accounting for 8.92% of total revenue (2023: 8.35%) [2]. - Research and development costs increased to RMB 238,929,000 in 2024 from RMB 220,098,000 in 2023, representing an increase of about 8.6%[38]. - The company plans to focus on four rapidly developing treatment areas: medical aesthetics, wound care, ophthalmology, and orthopedics, enhancing R&D and service capabilities[107]. Dividends and Share Repurchase - The board proposed a final dividend of RMB 0.60 per share (2023: RMB 1.00 per share) for the year ended December 31, 2024[2]. - The proposed final dividend for 2024 is RMB 0.60 per share, down from RMB 1.00 per share in 2023, with total proposed dividends amounting to RMB 138,023,000[43]. - The company repurchased a total of 2,492,100 H-shares during the year, with a cumulative total of 10,446,700 H-shares repurchased since March 2020[12]. - The company completed the first round of A-share repurchase from August 2023 to August 2024, acquiring a total of 2,015,674 A-shares[13]. - A second round of A-share repurchase is planned from November to December 2024, with an expected total of 492,746 A-shares to be repurchased[13]. Assets and Liabilities - Total assets as of December 31, 2024, were RMB 6,255.50 million, a slight decrease from RMB 6,389.55 million in 2023[9]. - The company’s cash and bank balances stood at RMB 2,629.31 million, down from RMB 2,739.99 million in the previous year[8]. - Total current assets were approximately RMB 3,658.27 million, a decrease of about RMB 91.87 million or 2.45% compared to 2023[121]. - Total current liabilities increased to approximately RMB 865.89 million, an increase of about RMB 149.94 million or 20.94% compared to 2023[123]. - The total liabilities amounted to approximately RMB 1,204.35 million, with a debt-to-asset ratio of 16.91%, an increase of 1.60 percentage points from 15.31% in 2023[128]. Revenue Breakdown - Revenue from mainland China was RMB 2,245,880 thousand in 2024, up from RMB 2,181,814 thousand in 2023, indicating a growth of about 2.9%[31]. - Medical beauty and wound care products generated RMB 1,189,225 thousand in revenue for 2024, up from RMB 1,052,801 thousand in 2023, marking an increase of about 12.9%[35]. - The revenue breakdown for 2024 shows that hyaluronic acid products contributed RMB 737.86 million (62.05% of total revenue), hEGF products contributed RMB 188.37 million (15.84%), and RF and laser equipment contributed RMB 262.99 million (22.11%)[75]. - The company's ophthalmic products generated revenue of RMB 853.42 million in the reporting period, a decrease of RMB 71.23 million or 7.70% compared to the previous year[84]. Market Position and Strategy - The market share of the hEGF product "Kanghesu" was 26.91% in 2023, maintaining its position as the second-largest in the domestic market[72]. - The company plans to continue expanding its product lines and enhancing service quality to increase market share amid ongoing reforms in the healthcare sector[67]. - The company is actively developing high-end artificial lens products with innovative processing techniques, including multifocal and extended depth of focus lenses[90]. - The company has secured exclusive distribution rights for high-end corneal reshaping lenses in mainland China, enhancing its product matrix and market responsiveness[93]. Regulatory and Compliance - The financial statements are prepared in accordance with International Financial Reporting Standards, with all values presented in Renminbi (RMB) rounded to the nearest thousand[18]. - The company has adopted revised accounting standards for the first time in this fiscal year, with no significant impact on its financial position or performance[21]. - The group plans to apply new and amended IFRS standards when they become effective[23].

Financial Performance - For the six months ended June 30, 2024, the company recorded revenue of approximately RMB 1,397.11 million, an increase of approximately RMB 91.40 million or 7.00% compared to RMB 1,305.71 million in the same period of 2023[9]. - Profit attributable to ordinary equity holders was approximately RMB 235.28 million, an increase of approximately RMB 30.04 million or 14.64% from RMB 205.24 million in the same period of 2023[9]. - Basic earnings per share for the period were RMB 1.01, compared to RMB 0.86 in the same period of 2023[9]. - The group reported a revenue of approximately RMB 1,397.11 million for the reporting period, an increase of RMB 91.40 million or 7.00% compared to RMB 1,305.71 million in the same period of 2023[38]. - Total comprehensive income for the six months ended June 30, 2024, was RMB 196,737,000, a decrease of 21.2% from RMB 249,563,000 in the same period of 2023[57]. - The profit attributable to equity holders of the parent company increased to RMB 235,283,000, up 14.6% from RMB 205,235,000 year-on-year[57]. - The group’s profit before tax for the six months ended June 30, 2024, was RMB 235,283,000, compared to RMB 205,235,000 for the same period in 2023, representing an increase of approximately 14.6%[84]. Revenue Breakdown - Revenue from the medical beauty and wound care product line was RMB 631.82 million, accounting for 45.22% of total revenue, with a year-on-year growth of 25.53%[11]. - Revenue from ophthalmic products was RMB 449.66 million, accounting for 32.18% of total revenue, showing a decline of 6.15% year-on-year[11]. - Revenue from orthopedic products was RMB 231.82 million, accounting for 16.59% of total revenue, with a slight increase of 0.28% year-on-year[11]. - Revenue from anti-adhesion and hemostatic products was RMB 68.87 million, accounting for 4.93% of total revenue, with a decline of 2.55% year-on-year[11]. - Revenue from the mainland China market was RMB 1,179,576 thousand, an increase of 11.3% from RMB 1,059,733 thousand in the previous year[71]. Research and Development - Research and development expenses for the period were approximately RMB 125.40 million, up by approximately RMB 24.01 million or 23.68% year-on-year, representing 8.98% of total revenue compared to 7.77% in 2023[9]. - The clinical trials for several key R&D projects progressed smoothly during the reporting period, including new high-oxygen contact lens products[12]. - The company continues to focus on the production and sales of bioproducts, medical-grade hyaluronic acid, and artificial lenses, with ongoing R&D in biotechnology and pharmaceuticals[70]. - Research and development costs increased to RMB 125,400,000 for the six months ended June 30, 2024, from RMB 101,391,000 in the same period of 2023, reflecting a growth of about 23.7%[78]. Dividends and Shareholder Returns - The board proposed an interim dividend of RMB 0.40 per share (tax included) for the six months ended June 30, 2024, compared to no dividend in the same period of 2023[9]. - The company proposed an interim dividend of RMB 0.40 per ordinary share, totaling RMB 93,192,000, compared to no dividend for the same period in 2023[82]. Market Position and Growth - The market share of the epidermal growth factor product "Kanghesu" was 26.91% in 2023, maintaining the second position in the domestic market[13]. - The company plans to expand the application of its epidermal growth factor product to multiple departments beyond traditional uses, enhancing its market reach[18]. - The Chinese medical aesthetics market is expected to grow by approximately 10% in 2024, with a compound annual growth rate of 10-15% over the next four years[17]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[154]. Cash Flow and Financial Position - Operating cash flow for the six months ended June 30, 2024, was RMB 380,712,000, an increase of 17.1% from RMB 325,038,000 in the same period of 2023[64]. - Cash and cash equivalents as of June 30, 2024, were approximately RMB 924.21 million, an increase of RMB 354.89 million from approximately RMB 569.32 million as of December 31, 2023[51]. - Total current assets as of June 30, 2024, were approximately RMB 3,720.36 million, a decrease of RMB 29.78 million or 0.79% from December 31, 2023[44]. - Total liabilities as of June 30, 2024, were approximately RMB 1,186.37 million, with a debt-to-asset ratio of 16.38%, an increase of 1.07 percentage points from 15.31% as of December 31, 2023[50]. Acquisitions and Investments - The company acquired 51% of Shanghai Shenhao Mijian Technology Development Co., Ltd. for a total consideration of RMB 36.2885 million, completed in June 2024[28]. - The cash outflow from investing activities related to the acquisition of Shenhao Mijian was RMB 16,009,000 after accounting for cash acquired[106]. Corporate Governance and Compliance - The interim financial report was approved by the board on August 16, 2024, and published on the Hong Kong Stock Exchange website[123]. - The company has complied with all applicable code provisions under the Corporate Governance Code during the reporting period[146]. - There were no significant legal proceedings or arbitrations involving the company during the reporting period[150]. Employee Compensation and Incentives - Employee compensation for the reporting period totaled approximately RMB 337.30 million, an increase of RMB 21.77 million from approximately RMB 315.53 million in the same period of 2023[46]. - The company has granted a total of 1,800,000 restricted shares under the 2021 A-share incentive plan, with the first vesting period completed[137]. - Total remuneration for key management personnel amounted to RMB 4,447,000 for the six months ended June 30, 2024, compared to RMB 3,471,000 for the same period in 2023, representing an increase of 28.1%[111].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 截至2024年6月30日止六個月期間之中期業績公告 截至2024年6月30日止六個月期間之中期業績摘要 • 報告期內，本集團共錄得營業收入約人民幣1,397.11百萬元（2023年同期：約 人民幣1,305.71百萬元），較2023年同期增加約人民幣91.40百萬元，增幅約 為7.00%。 • 報告期內，本集團研發開支約人民幣125.40百萬元，較2023年同期增加約人 民幣24.01百萬元，增幅約為23.68%，本集團研發開支佔收入比重為8.98% （2023年同期：7.77%）。 • 報告期內，本公司普通股權益持有人應佔利潤約為人民幣235.28百萬元（2023 年同期：約人民幣205.24百萬元），較20 ...

Financial Performance - The company's operating revenue for Q1 2024 was approximately RMB 645.99 million, representing a year-on-year increase of 5.68%[3] - Net profit attributable to shareholders for the same period was approximately RMB 97.54 million, reflecting a growth of 20.16% compared to the previous year[3] - The basic earnings per share for Q1 2024 was RMB 0.58, which is an increase of 23.40% year-on-year[3] - Net profit for Q1 2024 was RMB 92,488,777.12, up 9.0% from RMB 84,951,683.69 in Q1 2023[18] - Operating profit for Q1 2024 was RMB 114,427,839.61, slightly up from RMB 111,265,909.95 in Q1 2023[17] Research and Development - Research and development expenses totaled approximately RMB 64.90 million, accounting for 10.05% of operating revenue, which is an increase of 1.28 percentage points from the previous year[3] - Research and development expenses increased to RMB 64,900,123.30 in Q1 2024, representing a 21.1% rise from RMB 53,624,174.05 in Q1 2023[17] Cash Flow - The net cash flow from operating activities was approximately RMB 75.97 million, which decreased by 4.96% year-on-year[3] - Cash flow from operating activities for Q1 2024 was RMB 75,969,702.64, compared to RMB 79,930,962.49 in Q1 2023[21] - Cash flow from investing activities showed a net inflow of RMB 1,140,250,242.38 in Q1 2024, significantly higher than RMB 335,310,779.40 in Q1 2023[20] - Cash flow from financing activities resulted in a net inflow of RMB 42,137,675.19 in Q1 2024, compared to a net outflow of RMB 20,935,703.98 in Q1 2023[23] Assets and Liabilities - The total assets at the end of the reporting period were approximately RMB 7.19 billion, showing a slight increase of 1.23% from the end of the previous year[3] - The total assets as of March 31, 2024, amounted to CNY 7,192,952,822.94, an increase from CNY 7,105,496,951.15 as of December 31, 2023[12][16] - Current assets totaled CNY 3,745,333,949.09, slightly down from CNY 3,750,143,782.75 in the previous period[12] - Non-current assets increased to CNY 3,447,618,873.85 from CNY 3,355,353,168.40, indicating growth in long-term investments[13] - Total liabilities decreased to CNY 1,070,720,682.01 from CNY 1,088,203,977.97, reflecting improved financial stability[15] - The company's equity increased to CNY 6,122,232,140.93 from CNY 6,017,292,973.18, showing a positive trend in shareholder value[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,438[7] - The top shareholder, Jiang Wei, holds 28.17% of the shares, amounting to 47,520,000 shares[8] - The number of shares held by the top ten unrestricted shareholders reflects significant ownership concentration, with Jiang Wei holding 47,520,000 shares[10] Inventory and Receivables - Accounts receivable slightly increased to CNY 328,757,543.44 from CNY 327,861,290.31, suggesting stable revenue collection[12] - Inventory levels rose to CNY 533,642,335.66 from CNY 526,173,607.73, which may indicate preparation for increased sales[12] Other Financial Metrics - The company reported a decrease in other comprehensive income, with a net amount of RMB -21,216,593.79 in Q1 2024 compared to RMB 3,063,929.44 in Q1 2023[18] - Cash and cash equivalents were reported at CNY 2,677,447,776.76, down from CNY 2,740,678,648.51, indicating a reduction in liquidity[12]